Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (284)	10/11/2005 2:21:15 AM
From: tuck	Respond to of 447

Agree on all counts. I shorted EYET after approval (call made on the Biotech Short Candidates thread -- feel free to check it out and contribute Subject 50514 ) for much the same reasons. And if the general feeling among eye docs is that whatever Macugen can do Lucentis can do better, than sheesh, Genentech should be paying a chunk for EYET's trials! Your concept that Lucentis would be used off label in DME and CRVO is probably a good one, assuming reimbursement issues don't crop up. I established a position a few days ago on the theory that all this crap was priced in. Since Lucentis is perceived to be such a slam dunk, any weakness in ANCHOR data might now help OSIP. I have a position in DNA, established in the $83 range, also a few days ago (tomorrow will be another interesting day for me). The combination seemed smart to me at the time, until the Tarceva shortfall came up even worse than scrips had indicated. Cheers, Tuck